Comparison · Blood

ApoB vs. LDL: the heart marker your physical skipped

LDL-C weighs the cargo; ApoB counts the particles that carry it. Why the particle count predicts risk better, and the range worth aiming for.

October 8, 20265 min readBy the layers team

A standard lipid panel reports LDL cholesterol: the total mass of cholesterol riding inside low-density lipoprotein particles. It is a measure of cargo. Atherosclerosis, though, is started by the vehicles: particles that cross the artery wall and stay there. Apolipoprotein B is the structural protein those particles are built on, and each one carries exactly one copy.

Measuring ApoB therefore counts every atherogenic particle in circulation: LDL, VLDL, their remnants, and Lp(a). For most people the two measures rise and fall together. For a large minority they do not, and that is where the distinction earns its place on a panel.

Where the two disagree

LDL particles are not uniform; they range from large and cholesterol-rich to small and cholesterol-poor. With insulin resistance, elevated triglycerides, or metabolic syndrome, particles shift small and carry less cholesterol each, so LDL-C can read normal while the particle count sits high. The reverse pattern exists too, and it matters just as much: discordance analyses consistently show that risk tracks the ApoB level, not the LDL-C level.

This is the person a standard panel reassures incorrectly: triglycerides elevated, LDL-C unremarkable, ApoB never measured.

What the numbers show

In the UK Biobank primary-prevention cohort, ApoB predicted myocardial infarction at a hazard ratio of 1.27 per standard deviation, and when ApoB, non-HDL-C, and LDL-C were modeled together, only ApoB remained independently associated, a result that held in people with established disease as well.

An earlier meta-analysis of twelve prospective studies covering 233,455 participants ranked the three the same way: relative risk per standard deviation was 1.43 for ApoB, 1.34 for non-HDL cholesterol, and 1.25 for LDL-C.

The ranges in use

The 2019 European guidelines treat ApoB measurement as a class I recommendation in people with high triglycerides, diabetes, obesity, or very low LDL-C, and note the assay is more analytically reliable than calculated LDL-C. Their secondary goals: under 100 mg/dL at moderate risk, under 80 at high risk, under 65 at very high risk. The 2018 American guideline uses ApoB at or above 130 mg/dL as a risk-enhancing factor and considers measurement reasonable once triglycerides persist above 175 mg/dL.

LDL-C remains the primary treatment target in both documents; ApoB is the cross-check that catches the people the primary number misses.

What to do with it

ApoB is a standardized, inexpensive assay, yet most routine physicals still omit it. One measurement establishes your baseline and whether you are concordant or discordant with your LDL-C; from there it responds to the same interventions lipids do, on a timescale of weeks. Your clinician, not an article, should set your target. The useful step is making sure the number exists at all.

Sources

Keep reading